Anebulo Pharmaceuticals, Inc. (ANEB)

Market Cap	61.20M
Revenue (ttm)	n/a
Net Income (ttm)	-9.35M
Shares Out	25.93M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,973
Open	2.390
Previous Close	2.350
Day's Range	2.250 - 2.815
52-Week Range	1.620 - 4.050
Beta	-0.99
Analysts	Strong Buy
Price Target	6.67 (+182.63%)
Earnings Date	May 15, 2024

About ANEB

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2021
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: ANEB

Analyst Forecast

According to 3 analysts, the average rating for ANEB stock is "Strong Buy." The 12-month stock price forecast is $6.67, which is an increase of 182.63% from the latest price.

Price Target

$6.67

(182.63% upside)

Analyst Consensus: Strong Buy